Inherit For Three Thousand Years

Just as reports on this exhibition of contemporary artists were in full swing from the outside world, a series of sniping methods against Tiansheng Medicine have quietly begun.

First, the front page headline of the "Hong Kong Island Daily" published heavy news, publicly questioning Tiansheng Pharmaceutical's financial fraud.

Then many media followed up on the news, and under the overwhelming negative publicity, Tiansheng Pharmaceutical's stock price fell sharply.

In just three days, Tiansheng Pharmaceutical, which had a market value of 102.5 billion at its peak, lost nearly 10 billion in market value, and its market value could be as high as 90 billion.

Tiansheng Pharmaceutical launched an emergency tackling problem, angering the "Hong Kong Island Daily" and other unscrupulous media for deliberately exaggerating the facts, causing huge losses to the company. Tiansheng Pharmaceutical has sent a lawyer's letter to the "Hong Kong Island Daily" and other 6 media, expressing that they will be held accountable. The legal responsibilities of these unscrupulous media.

Qin Huali himself is the big benefactor behind the "Hong Kong Island Daily". He completely ignored the warnings of Tiansheng Medicine and continued to publish various negative news about Tiansheng Medicine.

Within a week, the market value of Tiansheng Pharmaceutical continued to shrink, from 100 billion to 86 billion.

Tiansheng Pharmaceutical tried every means to refute the rumors, and finally stopped the decline in the stock price. The second wave of attacks against Tiansheng Pharmaceutical came soon after.

Still, the "Hong Kong Island Daily" was the first to disclose the news that Tiansheng Pharmaceuticals invested a huge amount of money to research new drugs for the treatment of cardiovascular and cerebrovascular diseases, which had serious side effects and finally announced that the study had failed.

The content of this report is very detailed, and all the details of the research process have been disclosed.

The final failure of this drug directly led to a huge research investment of 5 billion accumulated over the years.

The outside world is very optimistic and supportive of Tiansheng Pharmaceutical's investment in the research and development of original research drugs. Moreover, in recent years, the research and development of this original research drug has been very smooth, and good news will be disclosed from time to time, which has played a positive role in raising the stock price.

Everyone knows that the investment in the original research drug is a bottomless pit. It is not easy to get the research results. Success is gratifying, and failure is commonplace.

But the mistake of Tiansheng Pharmaceutical is that it is too high-profile for research and development, and it has repeatedly used this method to increase the expectations of investors, thereby pushing up the stock price. This has led to the fact that the majority of investors can only accept success and cannot accept the cruel reality of R&D failure.

Now announcing that the final study has failed is a huge blow to confidence.

As much as Tiansheng Pharmaceutical has increased its share price with the help of new drug research and development, the magnitude of the decline is now. Even under the deliberate promotion of the sniper team, the decline was greater and faster.

On the day the news was disclosed, Tiansheng Pharmaceutical’s stock price plummeted again.

The negative news this time is real, and various real hammers have been continuously disclosed. Tiansheng Pharmaceutical’s dry explanation and the explanation of continuing to increase investment in original research drugs are of no avail.

Tiansheng Pharmaceutical’s stock price continued to fall after the sharp drop. In just five days, the original market value of 100 billion yuan shrank to 65 billion yuan.

It can be said that the management of Tiansheng Pharmaceutical has been exhausted during this period and tried every possible means to stop the sinister situation of the continued decline in the stock price.

Just when the majority of investors thought that Tiansheng Pharmaceutical's stock price had bottomed out and was about to rebound, the real fatal blow came suddenly.

Yuanhang Pharmaceutical and KPG Pharmaceutical Research Institute jointly held a press conference and invited reporters from major media to come.

The name of Yuanhang Pharmaceutical is little known. It is only a medium-sized pharmaceutical company in Nanyang. However, the KPG Pharmaceutical Research Institute is a big name. In the past few years, it has successively launched a number of best-selling drugs. For this joint press conference, the major players The media still attaches great importance to it.

The content of such a high-profile press conference is really amazing.

The two new best-selling drugs for the treatment of cardiovascular and cerebrovascular diseases of the Kpg Institute of Drug Research, and the exclusive patent authorization for the next 15 years, were won by Yuanhang Pharmaceutical in one fell swoop.

If the news is limited to this, it is not enough sensation, but if the authorized patents of these two drugs were snatched from Tiansheng Pharmaceutical, the influence of this news will be great.

"Hong Kong Island Daily" has the fastest response. Just after the press conference, a detailed analysis of this piece of information was posted on the official website.

Through the disclosure of the "Hong Kong Island Daily", stockholders learned that the sales performance of Tiansheng Pharmaceutical has increased year by year in the past few years, and the main contributors have turned out to be the two new drugs of kpg.

The profits of these two new drugs accounted for nearly half of the annual profits. Originally, this was good news to increase the stock price, but now Tiansheng Pharmaceutical has not obtained the subsequent patent license, the good news suddenly became a reminder.

Losing the patent licenses for these two drugs means that Tiansheng Pharmaceutical will lose nearly half of its profits every year, which is simply unbearable.

This blow is fatal!

The disclosure of this news is equivalent to digging out the main root of the big tree of Tiansheng Medicine. If you are not careful, Tiansheng Medicine is in danger of collapsing.

Down... down... or down!

Tiansheng Pharmaceutical’s share price began to fall precipitously, and in just three days, it fell below the issue price.

A week later, the market value of Tiansheng Pharmaceutical has shrunk to 45 billion.

At this point, the stock price has bottomed out, and there is basically no room for shrinking.

Tiansheng Pharmaceutical is not an asset-light Internet stock. The market value of 45 billion is already underestimated and it is impossible to continue to fall.

The outstanding shares of Tiansheng Pharmaceutical accounted for 40% of the total share capital. Qin Huali's acquisition team, together with Swire Investment, acquired 30% of the shares from the market, and the acquisition capital was only 16 billion yuan.

Things came too suddenly. Zeng Zhaoquan was very wary of the two major shareholders who suddenly appeared. He wanted to increase his shareholding, but unfortunately he couldn't get the funds for a while.

When he mortgaged his shares and successfully obtained the loan, there were not many circulating shares in the market. Zeng Zhaoquan only increased his shareholding from 35% to 40%.

For the acquisition of Tiansheng Pharmaceutical this time, the reason why Xiao Yao entrusted Qin Huali Lilly to dominate instead of Swire Investment to dominate is to rely on Qin Huali's personal connections.

If only operating in the financial market, Swire Investment is professional enough, but when it comes to off-market acquisitions, Qin Huali's personal energy is very important.

Tiansheng Pharmaceutical's equity is relatively dispersed. Zeng Zhaoquan is the largest shareholder, accounting for 35% of the total share capital. The circulating shares in the market account for 40%, and the remaining 25% is in the hands of seven shareholders. The largest one owns 8.7% of the shares, and the smallest one owns 1.2% of the shares.

The negotiations with these 7 shareholders fully demonstrated Qin Huali's powerful energy. He invested a total of 13 billion yuan at an average premium of 15% and successfully won the 25% of the shares.

At this point, Qin Huali has taken 55% of the shares and invested a total of 29 billion yuan in acquisition funds.